11:30 AM EDT, 05/14/2024 (MT Newswires) -- Cardiol Therapeutics ( CRDL ) working on treatments for heart disease, on Tuesday said its Phase II trial evaluating the impact of CardiolRx on myocardial recovery in patients with acute myocarditis (ARCHER trial) was the subject of an oral presentation at the World Congress on Acute Heart Failure 2024, May 11 - 14 in Lisbon, Portugal.

The trial design, rationale, and blinded baseline data on the first 50 patients was presented. Concurrently the journal ESC Heart Failure, which is dedicated to advancing knowledge about heart failure worldwide, has accepted the manuscript describing the rationale and design of the ARCHER trial for publication, the company said.

Cardiol said the ARCHER trial has now exceeded 85% of target patient enrollment. It added that the MAvERIC-Pilot Phase II study, investigating CardiolRx for recurrent pericarditis, expected to report topline results in early June.

The company's shares were last seen down $0.01 to $3.00 on the Toronto Stock Exchange.

Price: 3.00, Change: -0.01, Percent Change: -0.33